The CTLA-4, PD-1 track is crowded, and the development of the next generation of tumor immunotherapy is a new target for drug companies
In order to adjust the development layout, domestic pharmaceutical companies are accelerating "slimming"
Multi-pharmaceutical companies signed overseas licensing agreements to accelerate international market layout
Overweighting the best-selling anti-virus variety, Sunshine Pharmaceuticals grabs the second domestic company
In the first quarter, over 90 domestic biopharmaceutical companies completed financing
Baiji Baiji, Nuocheng Jianhua, Hengrui and other pharmaceutical companies enter the tens of billions of BTK inhibitor market
Pharmaceutical companies start the "buy, buy, buy" model to ease the "mid-life crisis"
Recently, many multinational pharmaceutical companies have made frequent moves!
The average R&D investment of domestic pharmaceutical companies has increased, and innovation is pressing the "acceleration button"!
Domestic pharmaceutical companies have reached a number of license-out transactions, further expanding overseas markets
pharmaceutical machine companies have attracted the attention of securities companies
Since March, pharmaceutical biology is still a hot research field for institutions, and these pharmaceutical companies have received high attention
Several pharmaceutical companies were fined for selling inferior drugs!
Last month, domestic biopharmaceutical companies reached 6 license-in transactions
The tide of cooperation between pharmaceutical companies has emerged again!
Senior executives of traditional Chinese medicine companies leave frequently, and more than 6 "leave" in March
Suzhou Goodtech plans to increase its capital by US$2 million in AICS, a subsidiary company in Malaysia
These pharmaceutical companies announced the first financial report after listing, and the word "profit" took the lead!
" is just a publicity stunt; a woman's meal order code was maliciously placed 20,000; Mengniu Group established a nutritional food company (April 26, 2022)
Nearly 40 pharmaceutical companies disclosed their performance in the first quarter of 2022, with a high pre-happy rate